Edaravone for the treatment of amyotrophic lateral sclerosis

Surveillance of using novel free radical scavenger, edaravone to investigate survival effect for ALS patients in Japan (SUNRISE Japan): A study design

(2017) M. Hirai et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

(2017) Koji Abe et al.   LANCET NEUROLOGY

Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis

(2017) Koji Takei et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation)

(2017)   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis

(2017)   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies

(2017) Alexander Kalin et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis

(2017)   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations

(2017) Yoshinobu Nakamaru et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Epidemiology of amyotrophic lateral sclerosis: A review of literature

(2016) P. Couratier et al.   REVUE NEUROLOGIQUE

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

(2014) Hiroshi Mitsumoto et al.   LANCET NEUROLOGY

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

(2014) Koji Abe et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation?

(2012) Tadashi Kanouchi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone

(2008) Akira Hishida   Clinical and Experimental Nephrology